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Abstract
Passive immunotherapy with monoclonal antibodies (mAb) targeted to specific tumor-associated
antigens is amongst the most rapidly expanding approaches to biological therapy of cancer.
However, until now a limited number of therapeutic mAb has demonstrated clinical efficacy in
selected neoplasia. Results emerging from basic research point to a deeper characterization of
specific biological features of neoplastic cells as crucial to optimize the clinical potential of
therapeutic mAb, and to identify cancer patients who represent the best candidates to antibody-
based immunotherapy. Focus on the tissue distribution and on the functional role of membrane
complement-regulatory proteins such as Protectin (CD59), which under physiologic conditions
protects tissues from Complement (C)-damage, might help to optimize the efficacy of
immunotherapeutic strategies based on C-activating mAb.
Introduction
In view of their potentiality to specifically target tumor
cells, antibody-based therapeutic strategies still represent
very attractive clinical approaches to cancer treatment. A
renewed interest in this field of cancer immunotherapy
has derived from the significant clinical results obtained
with anti-CD20 and anti-HER2 monoclonal antibodies
(mAb) in B cell malignancies and breast cancer, respec-
tively, and from the availability of new molecular tech-
niques such as recombinant DNA technology. Currently,
several mAb targeted to different tumor-associated anti-
gens (TAA) are employed in initial clinical studies of pas-
sive immunotherapy for solid and hematological
malignancies [1].
The tumoricidal activity of therapeutic antibodies
depends on different mechanisms of action such as inhi-
bition of downstream signaling events in the target cells.
In addition, therapeutic mAb can directly induce cell
death by triggering apoptosis or through "indirect" immu-
nologic mechanisms such as antibody-dependent cell-
mediated cytotoxicity (ADCC) and/or Complement (C)-
mediated cytotoxicity (CDC).
Over the past years, C-activating mAb have been exten-
sively utilized for the treatment of patients with tumors of
different histotype, in particular in patients with cutane-
ous melanoma which represents a "model disease" to
design and activate approaches of biological therapy in
cancer patients. Among therapeutic mAb that mediate
CDC and ADCC of target melanoma cells, anti-GD2 and
anti-GD3 mAb have been largely used in the clinical set-
ting, although with rather unsatisfactory results [2-4].
Nevertheless, in light of the promising results obtained in
pre-clinical studies, selected engineered C-activating mAb
are still utilized in clinical trials. Along this line, results of
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a phase I pilot clinical trial of human IgM mAb directed to
GM3 ganglioside in 9 patients with metastatic melanoma
have been most recently reported [5].
Several in vitro and in vivo studies, focused on the mecha-
nisms regulating C-activity and tumor-host interactions,
have provided insights on distinct biological features of
neoplastic cells that may affect the clinical efficacy of pas-
sive immunotherapy with antibodies or their derived
molecules [6]. Among the different mechanisms of
immune escape triggered by neoplastic cells, the expres-
sion of high levels of the C-regulatory proteins such as
Protectin (CD59) is emerging as an important strategy
that limits the potential clinical benefits deriving from
antibody-based immunotherapeutic approaches.
Discussion
The long-standing field of cancer immunotherapy clearly
needs well-substantiated pre-clinical evidences on the fine
modality of action of the different strategies utilized for
cancer treatment. In fact, a variety of therapeutic tools,
including C-activating mAb have been extensively utilized
in the clinic [2-4], in the absence of accompanying studies
designed to fully explore their biologic, functional and
clinical potential. As a direct consequence of this partially
"blind" therapeutic approach, several potentially useful
immunotherapeutic agents and approaches have been
rapidly dismissed, due to their limited clinical efficacy.
Indeed, opposite to chemotherapy, a much broader
number of variables must be taken into account to maxi-
mize the clinical accomplishment of immunobiologic
agents used as therapeutic tools in cancer patients.
As far as the clinical efficacy of passive immunotherapy of
cancer patients with therapeutic mAb that mediate the
activation of the C cascade, a major limitation is certainly
represented by the presence of a functional form of the C-
regulatory protein CD59 on the cell membrane of neo-
plastic cells, as well as in the tumor microenvironment
[7,8]. Among solid tumors, the expression and functional
role of CD59 has been well investigated in melanoma.
CD59 is broadly expressed on normal and neoplastic tis-
sues of melanocytic origin, with few non-CD59 expressing
melanomas, has a limited intra- and inter-lesional hetero-
geneity and, among known C-regulatory proteins, it rep-
resents the main restriction factor of C-susceptibility of
human melanomas [9,10]. Furthermore, a statistically sig-
nificant (r  = 0.914; p  < 0.001) inverse correlation was
identified between absolute levels of CD59 molecules
expressed on melanoma cells and their susceptibility to C-
mediated cytotoxicity induced by anti-GD3 mAb R24
[11]. Thus, melanomas from distinct patients were highly
susceptible to C-mediated cytotoxicity, while neoplastic
cells from other individuals were completely resistant to
C-cytotoxicity, even in the presence of elevated amounts
of C-sensitizing mAb R24 [11]. Conversely, no significant
correlation was found between levels of cell membrane
GD3 expressed on melanoma cells and their C-suscepti-
bility [11]. Thus, in spite of the efficient and rapid tumor
targeting potential of therapeutic mAb, these findings
strongly caution that their therapeutic efficacy may be
greatly implemented through the treatment of patients
bearing melanoma lesions that express weak to intermedi-
ate levels of CD59 and, thus, are more susceptible to the
cytolytic effect of autologous C activated by therapeutic
mAb. This notion is clearly not restricted to human
melanomas but rather represents a more general phenom-
enon; in fact, resistance to rituximab (anti-CD20)-medi-
ated C cytotoxicity is associated with high levels of CD59
expression on neoplastic cells of non-Hodgkin's lym-
phoma and multiple myeloma patients [12].
A soluble form of CD59 (sCD59) has been identified in
body fluids and in the culture supernatants of normal and
neoplastic cells [8,13,14]. Concerning melanoma, it was
demonstrated that the amounts of sCD59 released from
CD59-positive melanoma cells correlate with the levels of
CD59 expressed on the cell surface [8]. Noteworthy,
sCD59 released from melanoma cells blocks the binding
of anti-CD59 mAb to cell surface CD59 neutralizing their
functional activity [8]. In light of these evidences, the
recent observation that CD59 acts as a triggering co-recep-
tor for Natural Killer (NK) cell-mediated cytotoxicity [15]
identifies an additional protective role for CD59 in natu-
ral immunity. In fact, high amounts of circulating sCD59
detectable in sera of cancer patients may bind to NK cells
affecting CD59-mediated functional activation.
Conclusions
Much remains to be gained to make full use of the poten-
tial of immunotherapeutic agents in the clinical setting;
nevertheless, we are ever more generating pre-clinical and
clinical data that allow us to design prospective trials tak-
ing into strict account the characterization of the "biolog-
ical eligibility" of cancer patients to specific therapeutic
options, through the analysis of defined phenotypic char-
acteristics of their malignant lesions. Such a strategy will
ultimately lead to the identification and selection of
patients who represent the best candidates to specific
immunotherapeutic approaches.
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